Jim Simons
CDIO icon

Jim Simons’s Cardio Diagnostics CDIO Stock Holding History

Jim Simons’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9K Buy
+15,348
New +$40.2K ﹤0.01% 3145
2023
Q4 		– Sell
-593
Closed -$6K – 3772
2023
Q3 		$6K Buy
+593
New +$14.3K ﹤0.01% 3598

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

Jim Simons's CDIO Position: Q1 2026 in Review

Jim Simons opened a new position in Cardio Diagnostics (CDIO) in Q1 2026: 15,348 shares worth $29.9K. The stake represents ﹤0.01% of the portfolio and ranks #3145 among its holdings. This is a return to the name: Jim Simons previously reported a position in CDIO as recently as Q3 2023.

Jim Simons first reported a position in CDIO in Q3 2023 and has held it in 2 quarters since. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • Jim Simons held 15,348 shares of Cardio Diagnostics worth $29.9K as of Q1 2026.
  • Cardio Diagnostics was a new Jim Simons position in Q1 2026.
  • Cardio Diagnostics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #3145 holding.
  • Jim Simons first reported a position in Cardio Diagnostics in Q3 2023 and has held it in 2 quarters since.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.